Whitney Goldner

Dr. Whitney Goldner


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2018 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
MSManisha H. Shah
Manisha H. Shah
WGWhitney Goldner
Whitney Goldner
Thorvardur HalfdanarsonThorvardur Halfdanarson
Thorvardur Halfdanarson
EBEmily Bergsland
Emily Bergsland
JBJordan D. Berlin
Jordan D. Berlin
GZGriselda Zuccarino-Catania
Griselda Zuccarino-Catania
The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland tumors, pheochromocytomas, and paragangliomas. Management of NETs relies heavily on the site of the primary NET. These NCCN Guidelines Insights summarize the management options and the 2018 updates to the guidelines for locoregional advanced disease, and/or distant metastasis originating from gastrointestinal tract, bronchopulmonary, and thymus primary NETs.

12 January 2015 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
MKMatthew H. Kulke
Matthew H. Kulke
MSManisha H. Shah
Manisha H. Shah
ABAl B. Benson
Al B. Benson
EBEmily Bergsland
Emily Bergsland
JBJordan D. Berlin
Jordan D. Berlin
DFDeborah Freedman-Cass
Deborah Freedman-Cass
Neuroendocrine tumors (NETs) comprise a broad family of tumors that may or may not be associated with symptoms attributable to hormonal hypersecretion. The NCCN Clinical Practice Guidelines in Oncology for Neuroendocrine Tumors discuss the diagnosis and management of both sporadic and hereditary NETs. This selection from the guidelines focuses on sporadic NETs of the pancreas, gastrointestinal tract, lung, and thymus. Neuroendocrine tumors (NETs) comprise a broad family of tumors that may or may not be associated with symptoms attributable to hormonal hypersecretion. The NCCN Clinical Practice Guidelines in Oncology for Neuroendocrine Tumors discuss the diagnosis and management of both sporadic and hereditary NETs. This selection from the guidelines focuses on sporadic NETs of the pancreas, gastrointestinal tract, lung, and thymus.

13 December 2018 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Open access
PDF file
RHRobert I. Haddad
Robert I. Haddad
CNChristian Nasr
Christian Nasr
LBLindsay Bischoff
Lindsay Bischoff
NBNaifa Lamki Busaidy
Naifa Lamki Busaidy
DBDavid Byrd
David Byrd
LGLisa A. Gurski
Lisa A. Gurski
The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.

1 May 2016 in Journal of Oncology Practice
Verified
Journal Article
Closed access
WGWhitney Goldner
Whitney Goldner
Hypercalcemia has been reported to occur in up to 30% of patients who have a malignancy. Hypercalcemia is most common in those who have later-stage malignancies and predicts a poor prognosis for those with it. The most common causes include humoral hypercalcemia of malignancy mediated by parathyroid hormone–related peptide, osteolytic cytokine production, and excess 1,25-dihydroxy vitamin D production. However, the etiology is not always mediated by malignancy. Hypercalcemia can occur in those with malignancy and an additional etiology for hypercalcemia such as primary hyperparathyroidism or granulomatous diseases. This paper reviews the cancers associated with hypercalcemia and their proposed mechanisms, nontumor-mediated hypercalcemia, as well as diagnosis and treatment strategies for each condition.

8 January 2010 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
WGWhitney Goldner
Whitney Goldner
DSDale P Sandler
Dale P Sandler
FYFang Yu
Fang Yu
JHJane A. Hoppin
Jane A. Hoppin
FKFreya Kamel
Freya Kamel
TLTricia D. LeVan
Tricia D. LeVan
Thyroid disease is common, and evidence of an association between organochlorine exposure and thyroid disease is increasing. The authors examined the cross-sectional association between ever use of organochlorines and risk of hypothyroidism and hyperthyroidism among female spouses (n = 16,529) in Iowa and North Carolina enrolled in the Agricultural Health Study in 1993–1997. They also assessed risk of thyroid disease in relation to ever use of herbicides, insecticides, fungicides, and fumigants. Prevalence of self-reported clinically diagnosed thyroid disease was 12.5%, and prevalence of hypothyroidism and hyperthyroidism was 6.9% and 2.1%, respectively. There was an increased odds of hypothyroidism with ever use of organochlorine insecticides (adjusted odds ratio (ORadj) = 1.2 (95% confidence interval (CI): 1.0, 1.6) and fungicides (ORadj = 1.4 (95% CI: 1.1, 1.8) but no association with ever use of herbicides, fumigants, organophosphates, pyrethroids, or carbamates. Specifically, ever use of the organochlorine chlordane (ORadj = 1.3 (95% CI: 0.99, 1.7), the fungicides benomyl (ORadj = 3.1 (95% CI: 1.9, 5.1) and maneb/mancozeb (ORadj = 2.2 (95% CI: 1.5, 3.3), and the herbicide paraquat (ORadj = 1.8 (95% CI: 1.1, 2.8) was significantly associated with hypothyroidism. Maneb/mancozeb was the only pesticide associated with both hyperthyroidism (ORadj = 2.3 (95% CI: 1.2, 4.4) and hypothyroidism. These data support a role of organochlorines, in addition to fungicides, in the etiology of thyroid disease among female spouses enrolled in the Agricultural Health Study.

6 June 2012 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Open access
PDF file
MKMatthew H. Kulke
Matthew H. Kulke
ABAl B. Benson
Al B. Benson
EBEmily Bergsland
Emily Bergsland
JBJordan D. Berlin
Jordan D. Berlin
LBLawrence S. Blaszkowsky
Lawrence S. Blaszkowsky
MDMary A. Dwyer
Mary A. Dwyer
Neuroendocrine tumors comprise a broad family of tumors, the most common of which are carcinoid and pancreatic neuroendocrine tumors. The NCCN Neuroendocrine Tumors Guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine tumors. Most of the recommendations pertain to well-differentiated, low- to intermediate-grade tumors. This updated version of the NCCN Guidelines includes a new section on pathology for diagnosis and reporting and revised recommendations for the surgical management of neuroendocrine tumors of the pancreas.